Abstract: Mexico presents a complex population diversity integrated by Mexican indigenous (MI) (7% of Mexico's population) and Mexican mestizos (MMs). This composition highlights the importance of pharmacogenetic studies in Mexican populations. The aims of this study were to analyze the reported frequencies of the most relevant pharmacogenetic biomarkers and metabolic phenotypes in healthy volunteers from Mexican populations and to assess its interethnic variability across MI and MM populations. After a literature search in PubMed, and according to previously defined inclusion criteria, 63 pharmacogenetic studies performed in Mexican healthy volunteers up to date were selected. These reports comprised 56,292 healthy volunteers (71.58% MM). Allele frequencies in 31 pharmacogenetic biomarkers, from 121 searched, are described. Nine of these biomarkers presented variation within MM and MI groups. 
Introduction
It is well known that patients show interindividual variation in drug response even when they are treated with the same drug or are under the same dosage regimen. This variability is due to genetic and nongenetic factors that affect drug efficacy and safety. Age, organ function, nature of the disease and drug interactions are nongenetic factors that influence drug effects; however, there are several cases in which interindividual differences in drug response are mainly due to sequence variants in genes encoding drug-metabolizing enzymes (e.g. CYP2D6, CYP3A5, CYP2C9, CYP2C19, NAT2, TPMT, UGT1A1 and UGT1A4), drug transporters (e.g. ABCB1, ABCC2, OATP1B1 and SLCO2B1), or drug receptors (e.g. ADRB2, EGFR, DRD2, ERBB2 and RYR1) [1] [2] [3] [4] . Regulatory agencies, such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established a wide variety of genetic polymorphisms as biomarkers for therapeutic recommendations or safety warnings [5] [6] [7] . However, in Latin American countries, this information has not been widely considered in regulatory agencies. For instance, in Mexico, the Federal Commission for Protection against Health Risks (COFEPRIS) has not yet included pharmacogenetic considerations for therapeutic or safety recommendations.
Moreover, variations on drug-metabolizing enzymes and transporters not only affect drug response or toxicity but also impact the metabolism of endogenous substrates, and they have been related with neurological disorders as depression and suicide [8] [9] [10] .
The use of pharmacogenetic biomarkers in clinical practice should consider ethnic, cultural and socioeconomical variations, as well as the genetic heterogeneity among regions and nations [7, 11] . For example, several studies have shown the interethnic variability of biomarkers' frequencies as in the case of CYP2D6 [12] , CYP2C9 and CYP2C19 [13] , UGT1A1 [14] and HLA [15] [16] [17] [18] , whereas other investigations have reported the importance to perform pharmacogenetic studies in different ethnic groups [19] [20] [21] .
Ibero-American populations present a genetic heterogeneity and complex population diversity because of differences in human development index, colonial histories and population structure [11] . Therefore, the study of biomarkers on these distinctive populations is relevant to the development of pharmacogenetics and personalized medicine [22] .
Mexico is the 11th most populated country worldwide, with more than 112 million of inhabitants [23] . Geographically distant regions in Mexico have different population dynamics related to both ancestral components diversity and demographic conditions of each region [24] . Moreover, this country harbors one of the largest sources of pre-Columbian diversity and has a history of complex civilizations with different contributions to the current population [25] .
Mexican indigenous (MI) account for at least 60 different native groups, representing 7% of Mexico's current population [26] . This population, as well as other American indigenous populations and individuals with indigenous ancestry, could carry local private alleles rare or absent elsewhere, including functional and medically relevant variants, because of the lowest genetic diversity characteristic of these groups [27, 28] .
Mexican mestizos (MMs) have resulted because of the admixture of Amerindian indigenous groups for the past 500 years with European and, to a lesser extent, African populations [29] . MMs are known to be genetically different among the 30 Mexican states, with an Amerindian admixture ranging from 30% to 70% [26] . This unique demographic history highlights the importance to consider the genetic background of the populations in pharmacogenetic studies in Mexico [24] .
Although two previous reports have reviewed the pharmacogenetic studies conducted in Mexican populations [30, 31] , they have only considered some drug-metabolizing enzymes. Nevertheless, it is also important to describe the investigations of other biomarkers as drug transporters and receptors. Therefore, the aims of this study were to analyze the reported frequencies of the most relevant pharmacogenetic biomarkers and metabolic phenotypes in healthy volunteers from Mexican populations and to assess its interethnic variability across MI and MM populations. The present investigation is coordinated by RIBEF (Red Ibero-Latino Americana de Farmacogenética y Farmacogenómica, http://www.ribef.com), which addresses the study of pharmacogenetic data available in Latin American populations. RIBEF is a collaboration network that brings together more than 40 research groups with the aim to increase the pharmacogenetic knowledge in this multiethnic and multicultural region.
Methods
We performed a literature search in PubMed database on June 2015, using a previously defined methodology developed by the RIBEF Network to evaluate studies on Central American healthy volunteers [32] . The search included a selected panel of 121 pharmacogenetic biomarkers (see Supplemental data, Table 1 ). The search terms were "Mexico" and "pharmacogenetic biomarker", looked up one by one, for genotype studies and "probe drugs" and "Mexico" for phenotype reports exploration. The probe drugs searched were debrisoquine, sparteine, metoprolol, dextromethorphan, mephenytoin, omeprazole, tolbutamide, losartan, diclofenac, isoniazid and caffeine. From these quests, studies were further selected according to the following inclusion criteria: (i) studies reporting genotype, allele and/or metabolic phenotype frequencies for one or more of the biomarkers revised; (ii) only unrelated healthy volunteers included in the reports; and (iii) subjects studied originated from Mexico, either indigenous or mestizo populations (Figure 1 ). It also considers Mexican populations living in the United States, as a result of migration, who have complete Mexican linage and in whom pharmacogenetic studies have been performed. Studies in which the frequencies were calculated from control groups as of case-control studies were excluded from this review. All allele frequencies reported in this review correspond to the mutant variant. Frequencies of the wild-type alleles CYP2D6
Results
A total of 63 studies were included in the present review, wherein 56,292 healthy volunteers were genotyped for one or more of 31 pharmacogenetic biomarkers. Most of these individuals (71.58%) were MMs from different Mexican states, whereas the rest corresponded to various MI groups. Figure 2 shows the location of MM and MI populations within the United Mexican States where pharmacogenetic studies were performed. In addition, a study of MMs living in Los Angeles, CA, USA, was included because it met the inclusion criteria, and individuals with at least three Mexico-born grandparents were involved [39] . Only seven studies included ancestry information based on HLA alleles [40] , THO1 marker [41] , ancestry informative markers [42] [43] [44] and STRs [45, 46] .
Allele frequencies of pharmacogenetic biomarkers in Mexican populations
Reports of frequencies for 31 pharmacogenetic biomarkers in healthy MM or MI populations were found, namely ,  CYP2D6, CYP2C9, CYP2C19, CYP1A1, CYP1A2, CYP2B6,  CYP3A4, CYP3A5, NAT2, TPMT, MTHFR, UGT1A1, UGT1A4,  COMT, EPHX1, GSTM1, GSTP1, GSTT1, HLA-A, HLA-B,  ABCB1, ABCG2, TP53, XRCC1, EGFR, ERBB2, ERCC1, CCR5,  F5 , G6PD and VKORC1.
Frequencies of studied CYP2D6 alleles are shown in Table 1 . Currently, more than 100 CYP2D6 variants have been described [54] ; however, only 14 have been studied in seven MM populations and 13 MI groups. The average frequencies in MM populations of the CYP2D6 null alleles * 3, * 4 and * 5; the decreased enzymatic activity * 10, * 17 and * 41 alleles; and the standard activity * 35 allele showed differences with the MI groups (χ 2 test, p < 0.05). No differences were found in the frequencies of CYP2D6 alleles in the two studies for MMs from Chiapas reported.
Important differences in CYP2C9 * 2 and * 3 decreased activity alleles' frequencies were found between MM and MI groups because of the higher prevalence of these alleles in MM compared with MI populations (χ 2 test, p < 0.001) ( Table 2 ). CYP2C9 * 3 frequencies were different between the two MM studies from the Mexico City Area (χ 2 test, p < 0.05), and also between the two studies in Tarahumara (χ 2 test, p < 0.05). In regard to CYP2C19 alleles, only the CYP2C19 * 2 null activity variant has been found among Mexican populations, whereas the recent CYP2C19 * 17 variant, related with high enzymatic activity, has only been studied in MM populations ( [38] . The "predicted" phenotypes from genotype and allelic frequencies were calculated from original raw data whenever this information was not included in the corresponding publication.
The frequencies were compared with the weighted average of the frequencies calculated for the remaining groups, and to calculate the weighted average, the total number of subjects studied was taken into account. [39] . The frequency of the ABCB1 polymorphism rs1045642 (C3435T) described in MMs from Jalisco (60.00%, n = 111) was higher than those reported in two studies of MMs from Mexico City Area (47.70%, n = 269 and 51.00%, n = 300, respectively) and from the report in MMs from Los Angeles (48.00%, n = 93) (χ 2 test, p < 0.01) [39, 56, 58, 88] . For the variants rs2032582 (G2677T/A) and rs1128503 (C1236T) of ABCB1, only one 
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[77] [39] . Factor V Leiden (F5) was not found in any of 100 MM healthy volunteers from Mexico City Area [90] . The deletion in CCR5 gene has been reported for 4.40% of MMs from Nuevo León (n = 103) [91] , 3.00% of MMs from Yucatán (n = 242) [92] , and 1.60% of Mazatecos (n = 61), and it was not found in Mayos (n = 70) and Teeneks (n = 61) [93] . A higher frequency of CCR5 deletion was observed in MM populations in comparison to that reported for MI groups (χ 2 test, p < 0.05). Glucose-6-phosphate dehydrogenase (G6PD) deficiency, calculated with enzymatic assays, in 4777 MM healthy volunteers belonging to four states of the Pacific Coast (Sinaloa, Nayarit, Colima and Guerrero), three states of the Gulf of Mexico (Tamaulipas, Veracruz and Yucatan) and three northeastern states (San Luis Potosi, Coahuila and Durango) showed an average prevalence of 0.71%, suggesting that 1:140 males of the general population is G6PD deficient and consequently has a potential risk for the development of hemolysis in the presence of precipitating factors [94] . A similar G6PD deficiency frequency (0.77%) had been previously identified in 1938 MM individuals from the same four states of the Pacific Coast [95] . However, a slightly higher G6PD deficiency frequency (0.95%) was recently reported in 1993 MM subjects from four Northern States (Sonora, Baja California, Baja California Sur and Chihuahua) [96] . In contrast to the aforementioned studies, a much smaller frequency of 0.19% was recently determined in 21,619 MM newborns from a public hospital in Mexico City [97] . With regard to mutations implicated in G6PD deficiency, G6PDA-
and G6PDA-376G/468C genotype frequencies reported in MMs ranged from 48.78% to 78.57% and from 3.57% to 14.63%, respectively [94] [95] [96] [97] .
Two studies have determined the frequencies of VKORC1 variants and haplotypes in MM and MI healthy volunteers [26, 44] . The polymorphisms determined were rs3673 (g.45261860C > T), rs6484 (c. [26, 44] . Other VKORC1 haplotypes have been reported, and some of them are found in a low frequency among Mexican populations as H3, H4 and H5 ( < 3.00%), whereas haplotypes H1-H9 were found in more than the 95.00% of MM and MI populations [26] .
Studies on frequencies of "predicted" phenotype from genotype and "measured" phenotype
The frequencies of gPMs, gUMs and mPMs for CYP2D6; gPMs for CYP2C9; gPMs, gUMs, mPMs and mUMs for CYP2C19; and gSAs and mSAs for NAT2 and the frequencies of individuals homozygous or heterozygous for TPMT deficiency alleles determined in Mexican populations are shown in Table 6 . The average frequencies of gPMs and mPMs of CYP2D6 and the gPMs of CYP2C9 were higher in MM than in MI groups (χ 2 test, p < 0.05). In addition, for CYP3A4, one study that used omeprazole as probe drug reported a frequency of 11% of mPMs in 127 West Mexicans [99] . Omeprazole is not widely used as a probe drug for CYP3A4; however, the authors of this study considered that measuring the log of omeprazole/omeprazole sulfone is useful for the evaluation of CYP3A4 metabolic capacity. "Measured" phenotype has only been studied in four MM populations and one MI group. No information was found for the probe drugs debrisoquine, sparteine, metoprolol, mephenytoin, tolbutamide, losartan, diclofenac and caffeine.
Discussion
From the list of 121 pharmacogenetic biomarkers, 31 (25.62%) have been studied in Mexican healthy volunteers that represent 5.01E-4 of the total Mexico's population. This number is higher than the pharmacogenetic biomarkers previously reported for Central American healthy volunteers (12/104, 11.54%) [32] . The other two previous 68, 88, 20) 0.00 ND [51] reports in Mexico were performed using a different literature search strategy than the one used in the present study, and they only described the frequencies of seven [30] and six [31] drug metabolizing biomarkers, respectively. In the majority of Mexican states, at least one study was found, including pharmacogenetic biomarker frequency. However, in four Mexican states (Aguascalientes, Querétaro, Campeche and Quintana Roo), pharmacogenetic data are still missing. It is also necessary to enlarge this type of investigation where there is scarce information. For instance, individuals in several MI groups have been studied in Oaxaca, but MMs have not been studied. It would be of interest to compare the frequencies among these populations. Similarly, in Veracruz, only MMs have been studied, and there are many indigenous groups that have not been included in pharmacogenetic investigations [100] .
It is well documented that frequencies of CYP2D6 alleles and its metabolic phenotypes present interethnic variability [12] . In regard to Mexico, MMs from Durango and Mayos and Seris populations present a lower frequency of CYP2D6 * 2 than the rest of Mexican populations, whereas a higher frequency of this allele was found among MMs from Sonora and Coras. CYP2D6 allele multiplications were reported in a high frequency for MMs from Mexico City Area and for Huicholes. Interestingly, a high variability in frequencies of the CYP2D6 * 4 null allele was found in the studied MI populations, whereas CYP2D6 * 7, * 8, * 53 and * 82 have been scarcely studied among Mexican populations ( Table 1) .
Research of the CYP2D6 "measured" phenotype in MMs showed that 6.80%-10.00% are mPMs, whereas the "predicted" phenotype studies reported < 6.00% gPMs in MM populations and nearly none in MI. gUMs were found in both MM and MI populations, with frequencies as high as 20% for Guarijíos and Huicholes (Table 6 ). Variations on CYP2D6 metabolism could have clinical implications in the therapy of drugs as tamoxifen and codeine. Tamoxifen is frequently used for the prevention and treatment of estrogen receptor (ER)-positive breast cancer. Tamoxifen is a prodrug that requires metabolic activation to exert its pharmacological activity. CYP2D6 is the enzyme related to the conversion of tamoxifen into its active metabolite 4-hydroxytamoxifen. It has been found that in CYP2D6 PMs, an increased risk for breast cancer relapse is present [101] .
Codeine is an opioid analgesic indicated for the relief of mild to moderately severe pain. The analgesic properties of codeine are related to its conversion to morphine by CYP2D6. The percentage of codeine converted to morphine can be much higher in UMs that are at risk of severe toxicity. Current evidence supports that PMs have the possibility of lack of effect, and therefore, the avoidance of codeine use is recommended [102, 103] .
The CYP2C9 * 2 and * 3 alleles were the two most studied CYP2C9 alleles in Mexican healthy volunteers. The frequencies of these alleles were statistically higher in MM than in MI populations, probably due to the influence of Caucasian populations in admixture process and/or the Oriental genetic background in Amerindian populations [45, 57, 104] . The highest frequencies of CYP2C9 * 2 were observed for MM and MI populations from the northern states of Mexico (Nuevo León, Sonora, Zacatecas, Mayos and Tarahumara). Differences observed between the CYP2C9 * 3 frequencies reported for the two MM populations from Mexico City Area [58, 59] genotyping methods (PCR restriction fragment length polymorphism and real-time PCR) or the sample size (300 vs. 947) reported for MM groups. However, there is not a clear explanation for the difference between the two studies in Tarahumara [45, 59] . The frequency of gPMs was relatively low for MM and MI populations ( ≤ 2.10%) (Table 6 ), and the lack of studies on the CYP2C9 "measured" phenotype does not allow to consider if CYP2C9 genotyping is important for the drug dosage of CYP2C9 substrates in Mexico.
For CYP2C19, the main differences on allele frequencies were found among the different MI groups, with the highest frequency of the CYP2C19 * 2 allele, related to null enzymatic activity, present in Tarahumara from Chihuahua (31.00%) and the lowest in Purépechas from Michoacán (5.40%) and Tojolabales and Tzeltales from Chiapas (3.60% and 0.00%, respectively) ( Table 2) . Moreover, it is important to highlight the absence of the other null activity allele CYP2C19 * 3 in all the included Mexican populations studies. Both CYP2C19 PMs and UMs have been reported for MI and MM populations, with the highest frequencies of gPMs reported for MMs from Jalisco (6.30%) and Tarahumara (10.70%), whereas the only study of "measured" phenotype in healthy volunteers reported 6.00% of mPMs and 4.00% of mUMs in Jalisco (Table 6 ). The clinical impact of CYP2C19 poor and ultrarapid metabolism might be observed with clopidogrel. This is a potent antiplatelet drug indicated for the prevention of vascular thrombotic events in patients at risk, such as myocardial infarction, coronary artery disease and stroke. Clopidogrel is a prodrug, which is first oxidized to a 2-oxo-clopidogrel intermediate metabolite. The subsequent metabolism of this intermediate metabolite results in the formation of the active metabolite, a thiol derivative of clopidogrel that irreversibly blocks the platelet P2Y12 receptor, thereby inhibiting ADP-induced platelet aggregation. The main enzyme that is associated to its metabolism is CYP2C19. It has been found that the genetic variants CYP2C19 * 2, * 3, * 4, or * 5, related to a PM phenotype, are associated with an increased risk of cardiovascular events such as death, heart attack and stroke in patients taking clopidogrel [105] . The FDA and the EMA have included a warning on clopidogrel (Plavix) to make patients and health care providers aware that CYP2C19 PMs are at high risk of treatment failure and that testing is available [106, 107] .
Studies of NAT2 allele's frequencies in healthy volunteers have been only performed in MMs from Baja California and San Luis Potosí. NAT2 variants related to a slow metabolism (e.g.
* 5, * 6, * 7) were found in a high frequency among the studied MM populations ( > 30.00%) (Table 4) . Furthermore, 68.00% of MMs from Baja California were identified as mSAs (Table 6 ). Although there are only three studies of NAT2 in MM and none in MI populations, it is important to take into account the high prevalence of the SA phenotype, especially for drugs such as isoniazid, an important agent in the treatment of tuberculosis in combination with other drugs or alone as a prophylactic agent. Pharmacogenetic research has indicated that isoniazid concentrations as well as efficacy and toxicity of isoniazid are linked to the activity of the NAT2 enzyme. SAs are at greater risk to develop hepatotoxicity compared with rapid acetylators [108] . This evidence could be useful to improve the safety of isoniazid therapy.
The great number of frequencies reported for MTHFR polymorphisms in several Mexican populations also allows observing the interethnic variability among them (Table 4 ). In general, there is a high 677T allele frequency among the studied Mexican populations, with the highest frequencies observed in MI (46.30%-92.20%) and the lowest (38.00%-47.00%) present in MMs from Northern States of Mexico (Nuevo León, Baja California and Sonora), as it has been previously described [43, 109] . Nevertheless, the frequency of this allele in Mexican populations is greater to that reported in some European ( < 35.00% in Spain, the Netherlands, Hungary and Russia) and African (0.00%-3.00%) populations [110] , which could be due to an enrichment of this variant in Mexicans as a result of the admixture process and the Amerindian background [43] .
According to the studies reviewed here, frequencies of TPMT deficiency alleles were reported in up to 5.69% of the MMs from Mexico City Area, and individual carriers of at least one copy of a deficiency allele ( * 2, * 3A, * 3B and * 3C) account for more than 10.00% of MM population ( Table 4 ). The differences in the frequencies of TPMT * 3B alleles between the two studies in MMs from Mexico City Area may be due to the dissimilar genotyping methodologies used in the studies (DHPLC analysis and PCR restriction fragment length polymorphism) [45, 46] . This enzyme plays an important role in the metabolism of thiopurine drugs as 6-mercaptopurine (6-MP), an analog of the purine bases adenine and hypoxanthine, used as immunosuppressant in the treatment of autoimmune disorders, inflammatory bowel disease, debilitating skin diseases and various inflammatory eye conditions, as well as an antiproliferative drug in childhood acute lymphoblastic leukemia. 6-MP is inactivated via two major pathways. In one of them, a thiol methylation, catalyzed by the enzyme TPMT, forms the inactive metabolite methyl-6-MP, which prevents 6-MP from further conversion into active, cytotoxic thioguanine nucleotide (TGN) metabolites. Patients homozygous for TPMT deficiency alleles with little or no detectable TPMT activity, receiving standard doses of 6-MP, accumulate excessive cellular concentrations of active TGNs predisposing them to 6-MP toxicity. Also, heterozygous patients with low or intermediate TPMT activity accumulate higher concentrations of active 6-TGNs than patients with normal TPMT activity and are more likely to experience 6-MP toxicity [111] . The FDA and the EMAapproved label for 6-MP recommend testing for TPMT activity in patients with clinical or laboratory evidence of severe bone marrow toxicity, or repeated episodes of myelosuppression [112, 113] .
Only one study on UGT1A1 * 28 in healthy volunteers was found for Mexican populations. The frequency reported was 36.00%, and it was calculated from Mexicans living in Los Angeles, CA (Table 4 ). This allele results from seven TA repeats in the promoter region of UGT1A1 (TATA box) that reduces transcription efficiency, lowers the enzyme concentrations, and thus leads to the accumulation of substrates [114] . Irinotecan is a derivative of camptothecin, primarily used in the treatment of metastatic colorectal cancer. The drug is subject to a great interindividual variability in pharmacokinetic behavior, treatment efficacy, and the occurrence of unpredictable, sometimes severe, toxic side effects that might be life threatening in some patients. It has been recognized that inherited differences in the metabolism can affect the efficacy and toxicity of the drug. The risk of severe irinotecanassociated neutropenia is related in part to presence of the UGT1A1 * 28 variant, which is linked to reduced elimination of the irinotecan active metabolite SN-38 [115] . The FDA labeling of irinotecan includes a warning of greater neutropenia risk in those patients with reduced activity in the UGT1A1 enzyme [116] . Recently, a decision tree for UGT1A1 genotyping depending on initially intended irinotecan dose has been described in France to secure irinotecan administration [117] .
Warfarin is an oral anticoagulant with narrow therapeutic index and commonly prescribed in Mexico for the prevention of thrombosis and thromboembolism. The drug is supplied as a racemic mixture of R-and S-enantiomer; however, S-warfarin is more potent at inhibiting vitamin K reductase. It has been shown that variations in two genes are related with the individual response to warfarin dosing. One gene is CYP2C9, which metabolizes S-warfarin into its inactive form (S-7-hydroxywarfarin). The other gene, VKORC1 (VKOR complex subunit 1), plays a major role in the vitamin K pathway and is the target protein of warfarin. It has been found that individual carriers of the decreased activity variants CYP2C9 * 2 and CYP2C9 * 3 are more likely to need lower doses of warfarin and have an increased risk of bleeding complications. With regard to VKORC1, it has been shown that when the common G allele is replaced by the A allele (-1639G > A), lower warfarin doses are needed to inhibit VKORC1 and to produce an anticoagulant effect. Recently, the FDA stated that the patient's CYP2C9 and VKORC1 genotype information, when available, can assist in the selection of the starting dose [118, 119] . Previously, the low frequency of CYP2C9 * 2 and * 3 alleles found in Mexican populations was mentioned; however, the VKORC1 polymorphisms are highly prevalent in these populations. According to a recent report from MM and MI populations, 67% of MMs and 71% of MI are carriers of at least one copy of the -1639A allele and would better respond to a lower dose of warfarin [26] .
It is important to highlight the significant variation on the frequencies reported in three studies for the COMT polymorphism, in which two of them were performed in the Mexico City Area. These controversial data warrant further investigations in MM and MI populations, where studies are absent. Similarly, a lack of information in MI was observed for G6PD deficiency, whereas the frequency in MMs determined in one study [97] contrasts to the frequencies reported in the other three investigations [94] [95] [96] , probably due to the difference on the number of individuals studied.
HLA molecules show particularly high polymorphism with a great worldwide variability, and alleles that are highly frequent in one group being scant or even absent in others [81] . The variation on HLA alleles' frequencies described in this review are noticeable (Table 5) ; however, the clinical implication of all these alleles in Mexicans has not been determined. A recent report found a relation between HLA-A * 31:01:02 allele with cutaneous adverse drug reaction induced by carbamazepine [83] . The frequency of this allele in MMs varies from 2.40% to 8.25%, but in MI, the frequency reaches values of 19.80% in mixes from Oaxaca. In countries ethnically admixed such as Mexico, the genetic structure varies from one region to another. Therefore, pharmacogenetic studies in different populations are necessary to determine the biomarkers' frequencies corresponding to each region or ethnic group that could predict adverse drug reactions or help to personalize therapies.
The data described in the present study represent a valuable knowledge about the frequencies of pharmacogenetic biomarkers reported in MM and MI populations, where a significant frequency variation between these populations was found in several cases. In addition, it highlights the need to perform this type of study in some MM and MI populations where information is lacking.
Pharmacogenetic biomarkers will remain to accumulate in the future when its clinical significance is established. At present, the FDA and the EMA provide pharmacogenetic information in some drug labels to provide information to health care professionals. The data obtained in the present review show the presence of relevant frequencies of pharmacogenetic biomarkers, such as CYP2D6, CYP2C19, NAT2 and VKORC1, in MM and MI populations. Taking into account this information, we consider that it would be of interest that pharmacogenetic information in Mexico could be added in the labels of those drugs that are commonly used in our country, where relevant frequencies of biomarkers are found in Mexican populations, and for which clinical pharmacogenetic studies show that their use is important to improve drug efficacy and safety. Therefore, routine screening for pharmacogenetic biomarkers in the Mexican health care system should be analyzed in light of the biomarker prevalence in Mexican populations and the cost-benefit of its implementation.
